Bipolar disorder is a major medical, social and economic burden worldwide. However, the mechanisms of action of effective antibipolar disorder drugs remain elusive. In this paper, we review studies using a neuropharmacological approach in unanesthetized rats, combined with kinetic, biochemical and molecular biology techniques, showing that chronic administration of three Food and Drug Administration-approved mood stabilizers (lithium, valproate and carbamazepine) at therapeutically relevant doses, selectively target the brain arachidonic acid (AA) cascade. Whereas chronic lithium and carbamazepine decrease the binding activity of activator protein-2 and in turn the transcription, translation and activity of its AA-selective calcium-dependent phospholipase A 2 gene product, valproate appears to be a non-competitive inhibitor of long-chain acyl-CoA synthetase. The net overlapping effects of the three drugs are decreased turnover of AA but not of docosahexaenoic acid in rat brain phospholipids, and decreased brain cyclooxygenase-2 and prostaglandin E 2 . Although these observations support the hypothesis proposed by Rapoport and colleagues that the AA cascade is a common target of mood stabilizers, this hypothesis is not necessarily exclusive of other targets. Targeting the AA cascade with drugs or diet may be a useful therapeutic approach in bipolar disorder, and examining the AA cascade in patients might help in better understanding the disease.
Background on bipolar disorder
Bipolar disorder is generally characterized by changes in mood, varying from severe depression and mania (bipolar disorder I), to severe depression with hypomania (bipolar disorder II), mixed states or rapid cycling.
1,2 Bipolar disorder I afflicts 1.2-1.5% of the adult US population 3, 4 and depending on the severity of the disease these patients have a 5-to 17-fold higher suicide rate than the general population. 5 Bipolar disorder patients have poor outcomes and a high prevalence of medical illnesses. 6 Their overall quality of life is profoundly altered, as are social relationships, finances, career and family. Bipolar disorder is a major economic burden 7, 8 with the estimated 1998 lifetime cost of individual cases in the United States ranging from US$11 720 for persons with a single manic episode to $624 785 for those with non-responsive/chronic episodes. 9 Despite being treated pharmacologically for over 50 years 10 there is a clear need for improved treatment of the disease.
Approaches to studying mechanisms of action of drug in bipolar disorder
Numerous hypotheses have been proposed for the pathophysiology of bipolar disorder. On a broad level, these include abnormalities in neuroprotective, neurochemical, neuroendocrinological, neurostructural and genetic factors. Because of the complexity of bipolar disorder and lack of an accepted animal model, researchers model therapeutic mood-stabilizing drug regimens in rodents to elucidate the causes and pathophysiology of bipolar disorder. 11 Because of the relatively long time to onset of action, it is commonly thought that effects observed after chronic mood stabilizer administration may be more relevant to their therapeutic effect. However, despite there being a number of Food and Drug Administration-approved drugs for treating the disease, the mechanisms of action of these agents are not agreed upon. To date, no drug has been developed from a preclinical hypothesis specifically for bipolar disorder.
Many mechanisms of action have been proposed for mood stabilizers. Although not necessary, it would be helpful to find overlap between activities of mood stabilizers and/or the pathophysiology of the disease itself (that is, post-mortem brain samples). 12, 13 In this review, we summarize how chronic administration of therapeutically relevant doses of lithium, carbamazepine and valproic acid (valproate) (see Figure 1 for structures and Table 1 for therapeutic ranges) to rats, combined with kinetic, biochemical and molecular biological analyses, supports the hypothesis proposed by Rapoport and colleagues that mood stabilizers generally target the brain arachidonic acid (AA; 20:4nÀ6; Figure 2 ) cascade ( Figure 3) . [20] [21] [22] Although this review focuses on the AA hypothesis of bipolar disorder, this mechanism is not mutually exclusive of others and readers interested in other proposals on the mechanism of action of mood stabilizers, 23 involving inositol depletion, 24, 25 glycogen synthase kinase-3, 26 protein kinase C (PKC), 27 G proteins, 28 cyclic adenosine monophosphate or protein kinase A (PKA) 28 should consider these excellent reviews.
Overview of the AA cascade
Arachidonic acid is a nutritionally essential polyunsaturated fatty acid, found predominately in animal products. Although it can be synthesized from the nutritionally essential polyunsaturated fatty acid linoleic acid (18:2nÀ6), the rate of this reaction appears to be slow, 29 especially within the brain. 30 Thus, brain AA likely originates from the diet and/or from conversion of dietary linoleic acid in the liver. [31] [32] [33] [34] Earlier studies implicated AA as essential for growth and development, 35 but it is now recognized that AA is also extensively involved in brain signaling 36 and cholinergic 44, 45 receptor stimulation. AA and its derivatives are also ligands for several key transcriptional regulators, including peroxisomal proliferator activator receptors, 46 hepatic nuclear factor-4a, 47 prostaglandin receptors 48 and the liver X receptor, 49 collectively mediating numerous effects. The AA cascade ( Figure 3 ) starts with phospholipase A 2 (PLA 2 )-initiated hydrolysis of esterified AA from the stereospecifically numbered (sn)-2 position of membrane phospholipids. 50, 51 In the brain, these enzymes may include AA-selective calcium-dependent cytosolic PLA 2 (cPLA 2 ), calcium-dependent secretory PLA 2 (sPLA 2 ), or calcium-independent PLA 2 (iPLA 2 ). 52, 53 The majority of released AA is reincorporated into brain phospholipids via one of several long-chain acyl-CoA synthetases (Acsls) 54 and an acyl transferase, 55, 56 but a small portion of the released AA is b-oxidized or converted to eicosanoids via cyclooxygenase (COX)-1, COX-2, lipoxygenase, cytochrome P450 or epoxygenase. [57] [58] [59] Like AA, docosahexaenoic acid (DHA; 22:6nÀ3; Figure 2 ) is esterified in the sn-2 position of brain phospholipids. It is released by a PLA 2 (most likely iPLA 2 ), [60] [61] [62] [63] and the majority is then reesterified into brain phospholipids, while a portion of the non-esterified DHA can be converted to docosanoids which along with DHA, play important roles in brain signaling, 64 anti-inflammation 65 and neuroprotection. 36 The actions of DHA and the docosanoids are generally antagonistic to AA and its eicosanoid derivatives, respectively.
The kinetics (turnover and incorporation rates) of AA, DHA and other fatty acids in brain phospholipids can be calculated in vivo by applying a mathematical model to the brains of awake (unanesthetized) rodents that have been intravenously infused with the radiolabeled fatty acid and in which the brain is subjected to chemical or quantitative autoradiographic analysis. 56, 66, 67 From chemical analysis of the nonischemic high-energy microwaved brain, 68, 69 one can calculate incorporation coefficients and net incorporation rates of plasma unesterified fatty acids into Table 1 for the therapeutic plasma concentration of these drugs. 71 Quantitative autoradiography also allows one to determine incorporation coefficients for unesterified fatty acids from plasma into brain phospholipids within specific brain regions. With the synthesis of positron emitting 11 C fatty acids, similar to quantitative autoradiography, it is possible to measure the net uptake of unesterified fatty acids from plasma into brain regions in non-human primates 72 and in humans, 73, 74 using positron emission tomography (PET). For the nutritionally essential polyunsaturated fatty acids AA and DHA, this net uptake from the plasma unesterified pool approximates the rate of metabolic breakdown (loss) from the brain. 75, 76 Lithium and the AA cascade Lithium (Li þ ) was first used to treat bipolar disorder over 50 years ago and is still commonly used to treat its manic phase. 10 We have shown that chronic (6 weeks) intake of chow containing lithium chloride, to produce a therapeutically relevant plasma level (B0.7 mM) 20 ,77 of lithium, decreased AA turnover within brain phospholipids of unanesthetized rats. 20 This effect was specific for AA, as turnover rates of DHA and of palmitic acid (16:0) were not altered. 78 Chronic lithium also decreased brain COX-2 activity and protein level, and prostaglandin E 2 (PGE 2 ) concentration, 79 without altering the protein level of 5-lipoxygenase or cytochrome P450. 80 The decrease in AA turnover after chronic lithium administration was ascribed to lithium's ability to reduce brain expression (mRNA, protein and activity) of cPLA 2 , sparing sPLA 2 and iPLA 2 .
22,79 Because cPLA 2 is selective for AA release from brain phospholipids, a reduction in its activity was thought to explain how chronic lithium selectively reduced the turnover of AA and concentration of PGE 2 , but not the turnover of DHA or of palmitic acid. Further investigation showed that chronic lithium decreases DNA binding activities of the transcription factor activator protein-2 (AP-2), which regulates cPLA 2 gene transcription ( Figure 3 ), but not the DNA binding activities of four other transcription factors that regulate cPLA 2 gene expression, AP-1, glucocorticoid response element, polyoma enhancer activator 3 and nuclear factor-kB in rat frontal cortex. 81 The decreased AP-2-binding activity was ascribed to a combination of decreased AP-2a and AP-2b protein subunits and decreased AAdependent PKC activity, as PKC is a known regulator of AP-2. Because arachidonic (a) and docosahexaenoic acid (b) are greater than or equal to 20 carbons in length they are often referred to as long-chain polyunsaturated fatty acids (LCPUFAs). Much confusion has arisen because there are two commonly used naming systems for these fatty acids. The first system is extensively used in chemistry and this naming system labels double bonds starting from the carboxylic acid end of the fatty acid. Thus, this system leads to arachidonic acid being called 5cis, 8cis, 11cis, 14cis eicosatetraenoic acid and docosahexaenoic acid being called 4cis, 7cis, 10cis, 13cis, 16cis, 19cis docosahexaenoic acid. In the nutritional sciences, fatty acids are usually numbered from the methyl terminal end, also called the omega (nÀ) end of the molecule. Arachidonic and docosahexaenoic acids are nÀ6 and nÀ3 fatty acids, respectively. Furthermore, arachidonic acid is commonly referred to as 20:4nÀ6 (20 carbons, 4 double bonds, nÀ6) while docosahexaenoic acid is referred to as 22:6nÀ3 (22 carbons, 6 double bonds, nÀ3). Readers further interested in lipid nomenclature should refer to Fahy et al. (2005) . 19 Carbamazepine and the AA cascade
, an anticonvulsant first synthesized in 1960, 84 is now known to be beneficial in bipolar disorder. 1 Like lithium, chronic (30 days) carbamazepine administration, to produce therapeutically relevant plasma levels (53.6 mM), 85 decreased the turnover of AA but not of DHA in brain phospholipids of unanesthetized rats. 86 Similar to lithium, the decreased AA turnover was accompanied by decreased brain mRNA, protein and activity of cPLA 2 , but no change in sPLA 2 or iPLA 2 expression or activity. 85 Furthermore, chronic carbamazepine, like lithium, decreased brain COX-2 activity and PGE 2 , 79, 85 without altering 5-lipoxygenase or cytochrome P450 protein levels or leukotriene B 4 or thromboxane B 2 concentrations. 85 Similar to lithium, carbamazepine selectively decreased the DNA binding of the cPLA 2 gene-regulating transcription factor AP-2 ( Figure 3 ), but not other cPLA 2 gene-regulating transcription factors (AP-1, nuclear factor-kB, glucocorticoid response element and polyoma enhancer activator 3). 87 Carbamazepine's ability to decrease AP-2-binding activity was likely due to its ability to decrease cAMP-dependent PKA activity, a known activator of AP-2, 82 and the protein level of its AP-2a subunit.
Valproate and the AA cascade
Valproate (valproic acid; 2-propylpentanoic acid) is a branched-chain carboxylic acid and like carbamazepine is an anticonvulsant with proven mood-stabilizing properties in the treatment of acute mania. 88 Studies and case reports also indicate that valproate also has efficacy in mixed episodes. 89 Chronic (30 days) administration of valproate, to produce therapeutically relevant plasma levels (0.2 mM), 90 was shown to decrease the turnover rate of AA 90 but not of DHA 91 in brain phospholipids of unanesthetized rats. Similar to lithium and carbamazepine, chronic VPA decreased rat brain COX activity and PGE 2 concentrations, 92 without altering 5-lipoxygenase or cytochrome P450 protein levels or leukotriene B 4 or thromboxane B 2 concentrations. 92 Two weeks of valproate administration to rats decreased the ex vivo production of COX metabolites from isolated platelets and brain capillaries. 93 Valproate decreased COX-2 mRNA and the DNA binding activity of nuclear factor-kB, a transcription factor for COX-2 in rat frontal cortex. 94 It also selectively decreased the p50 protein component of nuclear factor-kB, without changing the protein or phosphorylation of inhibitor-kappa B a or p65 in rat frontal cortex. However, unlike lithium and carbamazepine, valproate did not change the expression or activity of cPLA 2 , nor did it alter sPLA 2 or iPLA 2 expression, or AP-2 DNA binding activity. 90, 92, 94 Because of this difference, we examined the effects of valproate on other enzymes regulating AA turnover within brain phospholipids, namely Acsl. By isolating microsomes from brain, we showed that valproate acts as an ordered noncompetitive inhibitor of Acsl in vitro (Figure 3 ), and that its K i for inhibiting arachidonoyl-CoA formation was lower than that for inhibiting formation of docosahexaenoyl-CoA or palmitoyl-CoA. 95 This may explain why valproate decreased the turnover of AA, but not of DHA, within brain phospholipids of the unanesthetized rat.
Observations related to AA in bipolar disorder patients
A small case-control study showed that serum PLA 2 activity was increased in patients with bipolar disorder, 96 and genetic mapping studies have demonstrated an alteration in the sPLA 2 gene of bipolar disorder patients. 97, 98 However, another study did not detect a difference in the BanI cPLA 2 and AvrII iPLA 2 polymorphisms, and in the sPLA 2 ATT repeat, between bipolar disorder patients and controls. 99 Several, clinical studies have suggested an increased hydrolysis of phospholipids in affective disorders, [100] [101] [102] including elevated plasma iPLA 2 activity, 103 elevated PGE 2 levels in plasma, 104 cerebrospinal fluid 105 and saliva 106 from depressed patients. Although basic studies indicate cross-talk between sPLA 2 and cPLA 2 , 107 it is unclear how peripheral markers of any PLA 2 would relate to the kinetics of AA in brain phospholipids. Maida et al. 108 have reported that cytosolic PGE synthase is decreased in the frontal and temporal cortex of bipolar patients and that this decrease did not occur in patients who were medicated prior to death. As noted by the authors, the functional implications of such changes as well as knowledge of the patient's mood state at time of death will be important for future studies. To date, no 11 C AA PET studies, which are feasible, [72] [73] [74] have been completed in patients with bipolar disorder or subjects chronically administered mood stabilizers. Because of the limitations in using peripheral markers to proxy brain AA kinetics, the completion of these studies will be important in connecting some of the preclinical observations (Table 2) to patients with bipolar disorder.
A small randomized clinical trial supplementing fish oils (containing 6.2 g of eicosapentaenoic acid (EPA; 20:5nÀ3) and 3.4 g of DHA day
À1
) showed benefits in bipolar disorder patients. 112 These findings have been confirmed in a small trial supplementing EPA (1-2 g day À1 , containing no DHA). 113 However, recently Keck et al. 114 found that adjunctive supplementation with 6 g day À1 EPA (containing no DHA) did not improve symptoms in bipolar patients. Because EPA is negligible in the brain while DHA represents over 10% of total fatty acids, it is not clear why EPA instead of EPA and DHA was used in these studies. Several reviews summarize the possible clinical benefits of supplementing nÀ3 polyunsaturated fatty acids in bipolar disorder, [115] [116] [117] [118] which may be of particular interest in light of the low intakes of DHA in the diet 119, 120 and because bipolar patients have low red blood cell DHA levels. 121 What stimulates the brain AA cascade?
Lithium, carbamazepine, valproate, lamotrigine and riluzole are reported to decrease N-methyl-D-aspartate (NMDA)-mediated signal transduction, 122, 123 which is altered in post-mortem samples of patients with bipolar disorder. [124] [125] [126] This is of particular interest to the AA hypothesis as NMDA-mediated receptor stimulation increases the intracellular level of calcium, an activator of cPLA 2 . 127 Basselin and co-workers 40, 128 found that acute administration of subconvulsant Collectively, these studies suggest that lithium alters AA signaling via PLA 2 as coupled to a variety of neuroreceptor subtypes (NMDA, serotonergic, dopaminergic and cholinergic) and are consistent with lithiumnormalizing neurotransmission imbalances that may account for the symptoms of bipolar disorder. Many of the above-mentioned receptors are regulated by G proteins, and are reported to be supersensitive to agonists in bipolar disorder. 133 This supersensitivity has been attributed to upregulation of the G protein a subunit 134 and decreased G protein receptor kinase 3 (GRK3). 135 GRK3 is a serine/threonine kinase involved in agonist-dependent homologous desensitization of G-protein-coupled receptors. Chronic lithium treatment increased GRK3 translocation from cytosol to membrane, providing another possible mechanism by which lithium can attenuate AA signaling in response to agonists. 136 Also of interest, intracerebroventricular infusion of Escherichia coli lipopolysaccharide for 6 days increased brain PGE 2 concentration, the activity of cPLA 2 , the incorporation rate of AA into brain phospholipids and the turnover of AA within brain phospholipids of the rat. 137, 138 Furthermore, the increased incorporation of AA into brain phospholipids can be blocked or reduced by preadministration of chronic lithium. 139 Clinical studies suggest that immune function is altered in bipolar disorder patients, and that they may be in a proinflammatory state, but much work remains before this is implicated as a causal factor. [140] [141] [142] Thus far, factors known to increase the turnover of AA within brain phospholipids of the unanesthetized rat have not been extensively studied. If reliable rodent models of bipolar disorder are developed, it would be useful to test if they are associated with increased AA turnover and AA incorporation into brain phospholipids using quantitative autoradiography and/or chemical analysis. In this regard, 15 weeks of nÀ3 polyunsaturated fatty acid deprivation in rats increased their depression and aggression scores 143 and these altered behavioral scores were associated with increased cPLA 2 activity, protein and mRNA as well as increased COX-2 protein and mRNA expression in the frontal cortex. 144 Approaches to developing novel therapeutics for bipolar disorder by targeting the AA cascade Chronic, therapeutically relevant doses of lithium, carbamazepine and valproate decrease the brain concentration of PGE 2 and the turnover of AA but not of DHA in brain phospholipids of the unanesthetized rat, albeit via different mechanisms ( Figure 3 and Table 2 ). Lithium and carbamazepine likely do so by downregulating brain cPLA 2 gene expression and activity, while valproate may selectively reduce arachidonoyl-CoA synthesis by inhibiting an Acsl. Because these drugs have different targets, this provides a rationale for studying/evaluating their effectiveness concomitantly 145 and could explain why the efficacy of valproate appears to be independent of prior responsiveness to lithium. 17 Although showing that three effective drugs overlap in an unanesthetized rat model is significant, examining the effects of other proven mood stabilizers in this and other models will be needed to further test and extend the hypothesis. One such example would be testing whether antipsychotic drugs, many of which have established efficacy in bipolar disorder, 146, 147 downregulate aspects of the brain AA cascade.
Chronic administration of lithium, carbamazepine and valproate to rats does not decrease the global turnover of DHA in rat brain phospholipids. DHA is a precursor to several docosanoid metabolites that are thought to be anti-inflammatory and neuroprotective relative to AA. 36, 65 Thus, decreasing AA signaling without altering DHA signaling may shift the balance of these two processes in favor of DHA and may be key to the therapeutic effectiveness of the mood stabilizers.
This review provides strong supporting evidence for the hypothesis that the AA cascade is a major target of drugs effective in bipolar disorder, [20] [21] [22] particularly the manic phase of the disease, but the targeting could be indirect. There are many upstream and downstream processes that could be more direct targets. For instance, a chronic downregulation of the AA cascade could alter signaling related to mood, including PKA activity or neuroendocrinological systems. 148 Conversely, the AA cascade could be a common link expanding upon other theories of mood stabilizers. Lithium decreases brain inositol levels, 24 but this occurs more rapidly than changes in mood, 149, 150 thus a prolonged decreased inositol signaling and PLC activity may be needed to decrease cPLA 2 activity (which requires 4,5 bisphosphatidylinositol and calcium) and the turnover of AA. 52 Because PKC activity can be increased by AA, 81, 83 decreased AA turnover could explain how mood stabilizers decrease PKC activity. 27 Thus far it appears that other suggested targets for lithium, carbamazepine and valproate overlap at the level of the AA cascade in the rat brain, and the hypothesis that drugs effective in bipolar disorder target the brain AA cascade is likely not exclusive of other hypothesized targets.
The concept of directly targeting COX-2 activity and PGE 2 formation for treating bipolar disorder has been proposed. 21 There is some indication that aspirin possesses mood-modulating properties, 151 and that celecoxib is a useful add on to reboxetine in treating major depression. 152 A recent randomized, double-blind, placebo-controlled trial in patients with bipolar disorder reported that adjunctive treatment with celecoxib produced rapid-onset antidepressant effects in patients experiencing depressive or mixed episodes. 153 The results of this study await confirmation in larger trials. Because AA, 37 arachidonoylCoA 47 and other non-COX-2-derived metabolites of AA 46 possess signaling properties and can regulate transcription, it is not clear if inhibiting COX-2 alone would be sufficient for mood stabilization. The results obtained from chronic lithium, carbamazepine or valproate administration to rats indicate that a reduction in COX-2, PGE 2 and/or a selective reduction in the turnover of AA may be required for mood stabilization. Future studies to clarify this are warranted.
Our results suggest that there are at least two ways of selectively decreasing AA turnover. One method is by selectively decreasing brain cPLA 2 and the release of AA from brain phospholipids as do lithium and carbamazepine, the other by selectively inhibiting Acsl activity and consequently arachidonoyl-CoA formation and AA turnover in brain phospholipids, as does valproate. The use of specific inhibitors of cPLA 2 154 or of Acsl 155,156 is a likely starting point for developing drugs that would selectively decrease the turnover of AA. A large number of potential compounds could be screened that selectively inhibit cPLA 2 or arachidonoyl-CoA formation in in vitro assays. 52, 95, 156, 157 Compounds demonstrating selectivity can then be further tested by administering them to rats and measuring brain PLA 2 or Acsl activities. Candidate drugs could be tested in the unanesthetized rat turnover model for efficacy prior to clinical studies.
In this regard, we tested the effects of topiramate, a drug that phase I clinical trials 158 and the quinpirole model of mania 159 had suggested to be effective in bipolar disorder. Despite achieving a therapeutically relevant plasma topiramate level of 18.1 mM after chronic treatment, and a decrease in body weight and serum leptin as reported by others, 160 topiramate did not alter cPLA 2 expression or any of the measured enzymes in the AA cascade, nor did it alter the turnover of AA or DHA in brain phospholipids of the unanesthetized rat. 161, 162 Supporting our negative findings, the results of four recent double-blind placebo-controlled trials demonstrate that topiramate is not an effective antibipolar drug, 163 a finding that was predicted by the AA models. 161, 162 Lamotrigine does not delay the onset of mania patients with bipolar disorder, although it does delay the onset of depressive symptoms 164, 165 and is effective in rapid cycling bipolar disorder. 166, 167 Similar to topiramate, 159 lamotrigine also decreases locomotive hyperactivity in the amphetamine model of mania. 168 Upon chronic administration to produce therapeutically relevant plasma levels in rats, lamotrigine did not decrease the turnover of AA in their brain phospholipids; 169 however, it downregulated COX-2 mRNA and protein expression. 170 Lamotrigine's ability to downregulate COX-2 may be related to its effectiveness in delaying the onset of depressive symptoms 164, 165 or in managing symptoms in rapid cycling bipolar disorder. 166, 167 After testing candidate drugs at the preclinical level, PET with 11 C-labeled AA and DHA could be used to study the metabolism of these polyunsaturated fatty acids in bipolar disorder patients and to proxy the effectiveness of candidate drugs in healthy humans. [72] [73] [74] Furthermore, drugs or conditions known to induce mania in susceptible individuals 171 could be studied using 11 C-labeled AA and PET. Because antidepressants can induce switching to mania when given to a depressed bipolar disorder patient, 146, [172] [173] [174] we examined the selective serotonin reuptake inhibitor fluoxetine in our models. Opposite to the antimanic drugs, chronic fluoxetine increased frontal cortex cPLA 2 activity, protein and mRNA expression along with the turnover of AA in brain phospholipids of the unanesthetized rat. 175, 176 However, chronic fluoxetine did not alter COX-2 protein or PGE 2 levels. 175 The increased cPLA 2 finding is broadly consistent with an earlier study in which fluvoxamine (also a selective serotonin reuptake inhibitor) increased cortical PLA 2 activity in rats. 177 Future studies examining other classes of antidepressants that differ in their switching rates 174 are warranted. Although these would be useful experiments to test in humans using PET, it should be recognized that it is not yet possible to solve all of the equations of the unanesthetized rat turnover model in humans. Once drugs that overlap with findings in Table 2 are discovered/developed and tested clinically, it will be possible to conclude whether or not targeting the AA cascade is a necessary feature of mood stabilizers.
Conclusions
To date, the mechanism of action of mood stabilizers used to treat bipolar disorder is not agreed upon. The hypothesis of Rapoport and colleaguyes [20] [21] [22] that effective mood stabilizers target the brain AA cascade by decreasing the turnover of AA but not of DHA in brain phospholipids of the unanesthetized rat as well as by decreasing rat brain COX-2 and PGE 2 concentrations has shown remarkable consistency in preclinical studies using lithium, carbamazepine, valproate and topiramate ( Figure 3 and Table 2 ). However, it is not known if a downregulation of the brain AA cascade is a necessary component of the mechanism of action of mood stabilizers. The confirmation of these findings in other model systems and further testing of this hypothesis in preclinical and clinical settings are warranted.
